Rasagiline mesylate
MAO-B inhibitor, Neuroprotective / Potent, irreversible monoamine oxidase (MAO) inhibitor selective for MAO-B (IC50=4.43 nM) over MAO-A (IC50=412 nM).1 Parkinson’s disease therapeutic.2 Displays neuroprotective and neurorestorative properties in a Parkinson’s disease zebrafish model.3 Prevents α-synuclein-induced dopaminergic neuronal death and rescues TrkB neurotrophic signaling.4 Enhances BDNF levels and is neuroprotective in Parkinson’s disease models.5
Biochemicals & reagents
161735-79-1
TVP-1012; Azilect
1) Youdim et al. (2001), Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B; Br. J. Pharmacol., 132 500 2) Cereda et al. (2017), Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study; J. Neurol., 264 1254 3) Cronin and Grealy (2017), Neuroprotective and Neuro-restorative Effects of Minocycline and Rasagiline in Zebrafish 6-Hydroxydopamine Model of Parkinson's Disease; Neuroscience, 367 34 4) Kang et al. (2017), TrkB neurotrophic activities are blocked by ?-synuclein, triggering dopaminergic cell death in Parkinson's disease; Proc. Natl. Acad. Sci. USA, 114 10773 5) Ledreux et al. (2016), BDNF levels are increased by aminoindan and rasagiline in a double lesion model of Parkinson's disease; Brain Res., 1631 34
-20°C
TARGET: Monoamine oxidase; Serotonin; Dopamine -- RESEARCH AREA: Neuroscience -- DISEASE AREA: Neurodegeneration